MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

Kodu・Aktsiate loetelu・Schrodinger Inc

Schrodinger Inc

Suletud

SektorTervishoid

11.33 -1.22

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

11.19

Max

11.77

Põhinäitajad
By Trading Economics
Sissetulek	169M 136M
Müük	33M 87M
Aktsiakasum	-0.18
Kasumimarginaal	155.644
Töötajad	850
EBITDA	67M 36M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+53.65% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	6. mai 2026

Turustatistika
By TradingEconomics
Turukapital	24M 850M
Eelmine avamishind	12.55
Eelmine sulgemishind	11.33

Uudiste sentiment

By Acuity

71%

29%

317 / 348 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

23.27 / 26.13 Toetus ja vastupanu

Schrodinger Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. apr 2026, 00:00 UTC

Uudisväärsed sündmused

ADB: Higher Energy Prices to Raise Production, Consumer Costs

10. apr 2026, 00:00 UTC

Uudisväärsed sündmused

ADB Projects Japan GDP Growth at 0.7% in 2026, 0.6% in 2027

10. apr 2026, 00:00 UTC

Uudisväärsed sündmused

ADB Projects South Korea GDP Growth at 1.9% in 2026, 1.9% in 2027

10. apr 2026, 00:00 UTC

Uudisväärsed sündmused

Extent of Slowdown Hinges on Duration of MidEast Conflict, ADB Says

10. apr 2026, 00:00 UTC

Uudisväärsed sündmused

ADB Projects India GDP Growth at 6.9% in 2026, 7.3% in 2027

10. apr 2026, 00:00 UTC

Uudisväärsed sündmused

ADB Projects China GDP Growth at 4.6% in 2026, 4.5% in 2027

10. apr 2026, 00:00 UTC

Uudisväärsed sündmused

ADB Pojects Australia GDP Grrowth at 2.0% in 2026, 2.9% in 2027

10. apr 2026, 00:00 UTC

Uudisväärsed sündmused

ADB Projects Taiwan GDP Growth at 7.6% in 2026, 4.0% in 2027

10. apr 2026, 00:00 UTC

Uudisväärsed sündmused

Geopolitical Risks Make Asia's Economic Outlook Highly Uncertain, ADB Says

10. apr 2026, 00:00 UTC

Uudisväärsed sündmused

Asia Regional Growth Likely to Moderate in 2026-2027, ADB Says

9. apr 2026, 23:44 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Talks -- Market Talk

9. apr 2026, 23:34 UTC

Market Talk

Gold Edges Lower Amid Lingering Inflation Concerns -- Market Talk

9. apr 2026, 23:14 UTC

Market Talk

Jefferies Upbeat on Australian Miners, But Recession a Key Risk -- Market Talk

9. apr 2026, 23:14 UTC

Market Talk

Global Equities Roundup: Market Talk

9. apr 2026, 23:07 UTC

Market Talk

Centaurus's Supply Deal with Glencore Supports Jaguar Development -- Market Talk

9. apr 2026, 22:54 UTC

Market Talk

Transurban Lacks Appeal as Higher Fuel Prices Slow Traffic -- Market Talk

9. apr 2026, 22:31 UTC

Uudisväärsed sündmused

Trump on Truth Social: 'That Is Not the Agreement We Have!'

9. apr 2026, 22:31 UTC

Uudisväärsed sündmused

Trump on Truth Social: 'Iran Is Doing a Very Poor Job, Dishonorable Some Would Say, of Allowing Oil to Go Through the Strait of Hormuz'

9. apr 2026, 20:57 UTC

Uudisväärsed sündmused

U.S. Oil Prices Are Back Near $100 After Israel Keeps Up Air Strikes on Lebanon -- Barrons.com

9. apr 2026, 20:55 UTC

Tulu

Stryker: Believes Incident Hasn't Had, and Isn't Reasonably Likely to Have, a Material Impact on 2026 Full-Year Guidance >SYK

9. apr 2026, 20:55 UTC

Tulu

Stryker: Determined Incident Had Material Impact on Operations, With Resulting Impact on Financial Results for 1Q >SYK

9. apr 2026, 20:55 UTC

Tulu

Stryker: Investigation of Cybersecurity Incident Remains Ongoing >SYK

9. apr 2026, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

9. apr 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. apr 2026, 20:40 UTC

Omandamised, ülevõtmised, äriostud

Blackstone Investment Positions Rowan to Continue Delivering Sustainable Data Center Capacity for World's Leading Technology Cos >BX

9. apr 2026, 20:39 UTC

Omandamised, ülevõtmised, äriostud

Blackstone Blackstone Acquired Significant Minority Stake in Rowan Digital Infrastructure >BX

9. apr 2026, 20:39 UTC

Omandamised, ülevõtmised, äriostud

Rowan Digital Infrastructure Announces Strategic Recapitalization

9. apr 2026, 20:25 UTC

Omandamised, ülevõtmised, äriostud

SBA Communications Stock Soars on Buyout Interest. What It Means for Tower Stocks. -- Barrons.com

9. apr 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

9. apr 2026, 19:30 UTC

Uudisväärsed sündmused

How Digital Currencies Have Helped Iran -- WSJ

Võrdlus sarnastega

Hinnamuutus

Schrodinger Inc Prognoos

Hinnasiht

By TipRanks

53.65% tõus

12 kuu keskmine prognoos

Keskmine 17.67 USD 53.65%

Kõrge 20 USD

Madal 13 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Schrodinger Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Schrodinger Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

23.27 / 26.13Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

317 / 348 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Schrodinger Inc

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. It has a research collaboration and license agreement with Novartis AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.